Reliable breakpoint cluster region (BCR)–Abelson (ABL) 1 measurement is essential for optimal management of chronic myelogenous leukemia. There is a need to optimize quality control, sensitivity, and reliability of methods used to measure a major molecular response and/or treatment failure. The effects of room temperature storage time, different primers, and RNA input in the reverse transcription (RT) reaction on BCR-ABL1 and β-glucuronidase (GUSB) cDNA yield were assessed in whole blood samples mixed with K562 cells. BCR-ABL1 was measured relative to GUSB to control for sample loading, and each gene was measured relative to known numbers of respective internal standard molecules to control for variation in quality and quantity of reagents,...
Abstract\ud Background\ud The monitoring of BCR-ABL transcript levels by real-time quantitative poly...
Purpose: Approximately 1–2% of chronic myeloid leukemia (CML) patients harbor atypical BCR-ABL1 tran...
In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlate...
Reliable breakpoint cluster region (BCR)–Abelson (ABL) 1 measurement is essential for optimal manage...
Accurate quantification of minimal residual disease during treatment of chronic myeloid leukaemia gu...
The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients treated with ...
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized t...
For patients with chronic myeloid leukaemia (CML), treatment guidelines recommend monitoring respons...
Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kinas...
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid ...
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid ...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for b...
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels ...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Abstract\ud Background\ud The monitoring of BCR-ABL transcript levels by real-time quantitative poly...
Purpose: Approximately 1–2% of chronic myeloid leukemia (CML) patients harbor atypical BCR-ABL1 tran...
In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlate...
Reliable breakpoint cluster region (BCR)–Abelson (ABL) 1 measurement is essential for optimal manage...
Accurate quantification of minimal residual disease during treatment of chronic myeloid leukaemia gu...
The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients treated with ...
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized t...
For patients with chronic myeloid leukaemia (CML), treatment guidelines recommend monitoring respons...
Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kinas...
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid ...
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid ...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for b...
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels ...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Abstract\ud Background\ud The monitoring of BCR-ABL transcript levels by real-time quantitative poly...
Purpose: Approximately 1–2% of chronic myeloid leukemia (CML) patients harbor atypical BCR-ABL1 tran...
In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlate...